Plain-English translation of NCT07066397 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial (Phase 1) testing a new treatment called FIT-CD19-CAR-T cells for patients with acute lymphoblastic leukemia (ALL) that has returned or stopped responding to standard chemotherapy. The treatment works by taking immune cells from your body, engineering them in the laboratory to recognize and attack leukemia cells, and then infusing them back into your bloodstream. This medication is designed to help your immune system eliminate the cancer cells that have become resistant to other treatments.
Current standard treatments don't work for everyone with aggressive leukemia, and some patients run out of options. This trial exists to see if this new cell-based treatment—which harnesses your own immune system in a new way—can be safe and effective for patients whose cancer has returned or stopped responding to chemotherapy.
You likely qualify if…
You likely don't qualify if…
You will first receive two chemotherapy drugs ( and ) to prepare your body for the new treatment—this is called conditioning chemotherapy. After that, you'll receive an infusion of the engineered immune cells through an IV line. You'll then be closely monitored for safety and to see how well the treatment works, with regular blood tests, physical exams, and other assessments. The exact duration and number of visits will depend on how your body responds, but you can expect frequent clinic visits, especially in the weeks after the cell infusion.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Taiwan
Phase
Safety & dosing
Sponsor
TriArm Therapeutics (Taiwan) Limited
Enrollment target
~12 participants
Started
July 2025
Primary completion
April 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Reta Ruan
TriArm Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.